Genetic fate of recombinant adeno-associated virus vector genomes in muscle

被引:186
|
作者
Schnepp, BC
Clark, KR
Klemanski, DL
Pacak, CA
Johnson, PR
机构
[1] Childrens Hosp, Columbus Childrens Res Inst, Columbus, OH 43205 USA
[2] Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43205 USA
关键词
D O I
10.1128/JVI.77.6.3495-3504.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Recombinant adeno-associated virus (rAAV) vectors are promising human gene transfer vectors, because they mediate long-term gene expression in vivo. The vector DNA form responsible for sustained gene expression has not been clearly defined, but it has been presumed that the vector integrates to some degree and persists in this manner. Using two independent methods, we were unable to identify rAAV integrants in mouse muscle. In the first approach, we were unable to recover host cell-vector DNA junctions from a lambda phage library generated using transduced mouse muscle DNA that contained a high vector copy number. Following this result, we devised a PCR assay based on the principle that integrated rAAV vector sequences could be amplified using primers specific for mouse interspersed repetitive sequences (B1 elements). Using this assay, we analyzed transduced mouse muscle DNA isolated from 6 to 57 weeks after injection and did not detect amplification above background levels. Based on the demonstrated sensitivity of the assay, these results suggested that >99.5% of vector DNA was not integrated. Additional analyses using a novel DNA exonuclease showed that the majority of the rAAV vector DNA in muscle persisted over time as transcriptionally active monomeric and concatameric episomes.
引用
收藏
页码:3495 / 3504
页数:10
相关论文
共 50 条
  • [41] Investigating the Role of DNA Replication in the Establishment and Maintenance of Recombinant Adeno-Associated Viral Vector Genomes
    Lyles, Jennifer K.
    Stankov, Sylvia
    Penaud-Budloo, Magalie
    Moullier, Philippe
    Snyder, Richard O.
    MOLECULAR THERAPY, 2020, 28 (04) : 440 - 440
  • [42] Production of recombinant adeno-associated virus vectors
    Zolotukhin, S
    HUMAN GENE THERAPY, 2005, 16 (05) : 551 - 557
  • [43] A Scalable and Accurate Method for Quantifying Vector Genomes of Recombinant Adeno-Associated Viruses in Crude Lysate
    Ai, Jianzhong
    Ibraheim, Raed
    Tai, Phillip W. L.
    Gao, Guangping
    HUMAN GENE THERAPY METHODS, 2017, 28 (03) : 139 - 147
  • [44] Pharmacology of Recombinant Adeno-associated Virus Production
    Penaud-Budloo, Magalie
    Francois, Achille
    Clement, Nathalie
    Ayuso, Eduard
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2018, 8 : 166 - 180
  • [45] Targeting of recombinant adeno-associated virus vectors
    Hallek, M
    Büning, H
    Ried, M
    Perab, L
    Kofler, D
    Gerner, F
    Wendtner, CM
    Leike, K
    Huttner, N
    Hutter, M
    CANCER GENE THERAPY, 2001, 8 (09) : 688 - 688
  • [46] Recombinant adeno-associated virus transduction and integration
    Schultz, Brian R.
    Chamberlain, Jeffrey S.
    MOLECULAR THERAPY, 2008, 16 (07) : 1189 - 1199
  • [47] Adeno-associated virus integration: virus versus vector
    R H Smith
    Gene Therapy, 2008, 15 : 817 - 822
  • [48] Adeno-associated virus integration: virus versus vector
    Smith, R. H.
    GENE THERAPY, 2008, 15 (11) : 817 - 822
  • [49] Adeno-Associated Virus Vector Design-Moving the Adeno-Associated Virus to a Bioengineered Therapeutic Nanoparticle
    Jaschke, Nico
    Buning, Hildegard
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (04) : 667 - 685
  • [50] Adeno-associated virus vector integration junctions
    Rutledge, EA
    Russell, DW
    JOURNAL OF VIROLOGY, 1997, 71 (11) : 8429 - 8436